



**CAVA HEALTHCARE INC.**  
PRESS RELEASE

## **CAVA HEALTHCARE ANNOUNCES PUBLICATION OF ALZHEIMER'S DISEASE RESEARCH IN THE LANCET**

**Vancouver, British Columbia, November 1, 2021** – Cava Healthcare Inc. ("Cava", "The Company") is pleased to report that its patented Alzheimer's Disease research has been published in the world's foremost medical journal, *The Lancet*.

Alzheimer's disease is a devastating neurodegenerative condition that leads to severe cognitive decay in older populations and worsens with age. The estimated cost of caring for people with Alzheimer's and other dementias in the USA alone was a staggering \$305 billion in 2020 (source: Alzheimer's Association) and is expected to reach \$1.1 trillion by 2050. The number of Americans living with Alzheimer's is predicted to nearly triple by 2050 without improvements in medical care. One characteristic sign of Alzheimer's disease is an accumulation of brain beta-amyloid proteins ("plaques"). In animal trials, Cava's patented technology has successfully demonstrated a 90% reduction of these plaques. This plaque removal resulted in a corresponding return to normal cognitive behavior after one month of treatment with the drug. Cava's therapeutic strategy involves use of the anti-cancer drug Axitinib to dramatically reduce aberrant cerebrovascular changes, to reduce plaque deposits, and to reverse cognitive decline.

The research appeared in *The Lancet*, EBioMedicine section (C.S.B. Singh, K.B. Choia, L. Munro, H.Y. Wanga, C.G. Pfeifer, and W.A. Jefferies, "*Reversing pathology in a pre-clinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics*", *EbioMedicine*, 71 (2021) 103503; <https://doi.org/10.1016/j.ebiom.2021.103503>). The authors show "*AD can be effectively treated in a preclinical model using an anti-cancer drug that inhibits aberrant neoangiogenic expansion*". The authors further note, "*Our study provides intriguing parallels between AD and otherwise disparate diseases where aberrant neoangiogenesis occurs, such as in the wet form of AMD and in various solid tumours. Repurposing previously approved anti-angiogenic drugs provides a clear path for entry into clinical trials for treating AD. The target for anti-angiogenics in AD is the disrupted neurovascular unit, which is readily accessible by orally administered drugs that enter the bloodstream. Thus, there is no requirement for these therapeutics to actively cross the intact BBB to enter the central nervous system. Finally, this study validates future clinical exploration of other approaches for halting and reversing aberrant cerebrovascular neoangiogenesis to treat AD.*"

The next step for this medical advancement is to take it into human clinical trials. Axitinib is already approved for use in treating renal cell cancer in the USA, Canada, Europe, the UK, and Australia; this should accelerate the process of repurposing the drug for use with Alzheimer's disease. If the research's animal trial results are successfully duplicated in humans, this new approach to the prevention and cure of Alzheimer's disease has the

potential to help an estimated 50 million people worldwide today, and countless millions to come.

The Company's business approach involves research, patenting, and licencing/selling its advances in healthcare and medicine. Cava continues to maintain its extensive patents portfolio and has extended patents coverage into further jurisdictions worldwide.

For further information, please contact Theo Warkentin at [theo@cavahealthcare.ca](mailto:theo@cavahealthcare.ca) or (604) 370-1757.

## **On Behalf of the Board of Directors**

**Theo Warkentin**  
CEO and Director

## **CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE**

Chronic and acute inflammation and poor immune function are at the core of developing disease. Cava is addressing this unmet healthcare challenge through isolation and characterization of novel compounds from medicinal plant extraction, creation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.

### **Cautionary Note Regarding Forward-Looking Statements**

*This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company's current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.*

*Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market*

*or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at [www.sedar.com](http://www.sedar.com).*

*Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.*